The evolving concept of treatment-resistant schizophrenia

Actas Espanolas de Psiquiatria

Volumn 39, Issue 4, 2011, Pages 236-250

  Quintero, Javier ^a   Del Cura, Eduardo Barbudo ^b   Lopez Lbor, Maria I ^a   Lopez lbor, Juan J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

Author keywords

Antipsychotics; Chronic schizophrenia; Comorbidity; Psychosis; Resistant schizophrenia; Schizophrenia; Treatment resistant schizophrenia

Indexed keywords

DRUG RESISTANCE; HUMAN; REVIEW; SCHIZOPHRENIA;

DRUG RESISTANCE; HUMANS; SCHIZOPHRENIA;

EID: 80053289196     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. American Psychiatric Association. DSM-IV-TR. Manual de Diagnostico y Estadistico de los Trastomos Mentales, cuarta edicion, texto revisado. Barcelona: Editorial Masson; 2002.
2. Andreasen NC, Carpenter WT Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005 Mar;162(3):441-9. (Pubitemid 40343909)
3. Essock SM, Hargreaves WA, Dohm FA, Goethe J, Carver L, Hipshman L Clozapine eligibility among state hospital patients. Schizophr Bull 1996;22(1):15-25. (Pubitemid 26081407)
4. Juarez-Reyes MG, Shumway M, Battle C, Bacchetti P, Hansen MS, Hargreaves WA. Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatr Serv 1995;46(8):801-6.
5. Elkis H, Meltzer HY. Refractory schizophrenia. Rev Bras Psiquiatr 2007 Oct;29 Suppl 2:S41-7.
6. Jaspers K. Psicopatologia General. Mexico, Fondo de Cultura Económica, 1996.
7. Meyer H, Taiminen T, Vuori T, Aijala A, Helenius H. Postraumatic Stress Disorder Symptoms Related to Psychosis and Acute Involuntary Hospitalization in Schizophrenic and Delusional Patients. The Journal of Nervous and Mental Disease 1999;187(6):343-52. (Pubitemid 29272885)
8. Angst J. European Long-Term Followup Studies of Schizophrenia. Schizophr Bull 1988;14(4):501-13. (Pubitemid 19129691)
9. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and metaanalysis. Am J Psychiatry 2005 Oct;162(10):1785-804. (Pubitemid 41428609)
10. Penn DL, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA. Psychosocial treatment for first-episode psychosis: a research update. Am J Psychiatry 2005 Dec;162(12):2220-32. (Pubitemid 41740199)
11. Schultz SK, Andreasen NC. Schizophrenia. Lancet 1999 Apr 24;353(9162):1425-30. (Pubitemid 29192426)
12. Bustillo JR, Lauriello J, Horan WP, Keith SJ. The Psychosocial Treatment of Schizophrenia: An Update. Am J Psychiatry 2001;158:163-75. (Pubitemid 32116510)
13. Turkington D, Kingdon D, Weiden PJ. Cognitive behavior therapy for schizophrenia. Am J Psychiatry 2006 Mar;163(3):365-73. (Pubitemid 44469376)
14. Peuskens J, Demily C, Thibaut F. Treatment of cognitive dysfunction in schizophrenia. Clin Ther. 2005;27 Suppl A:S25- 37. (Pubitemid 41356721)
15. Symptoms versus neurocognitive skills as correlates of everyday functioning in severe mental illness. Expert Rev Neurother 2006;6(1):47-56.
16. Csernansky JG, Kaplan J, Hollister LE. Problems in classification ofschizophrenicsas neuroleptic responders and nonresponders. J Nerv Ment Dis 1985;173(6):325-31. (Pubitemid 15079176)
17. Emsley R, Chiliza B, Schoeman R. Predictors of long-term outcome in schizophrenia. Curr Opin Psychiatry. 2008;21(2):173-7. (Pubitemid 351339873)
18. Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JM, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996;57 Suppl 9:5-9. (Pubitemid 26327751)
19. Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry 2007;68(2):e04.
20. Taylor DM, Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics. J Psychopharmacol 2000;14(4):409-18. (Pubitemid 32059788)
21. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45(9):789-96.
22. Kane JM. Management strategies for the treatment of schizophrenia 2. J Clin Psychiatry 1999;60 Suppl 12:13-7.
23. Pantelis C, Lambert TJ. Managing patients with " treatmentresistant" schizophrenia. Med J Aust 2003;178 Suppl:S62-S66.
24. Wilson WH. Reassessment of state hospital patients diagnosed with schizophrenia. J Neuropsychiatry Clin Neurosci 1989;1(4):394-7. (Pubitemid 19272402)
25. Mitelman SA, Buchsbaum MS. Very poor outcome schizophrenia: clinical and neuroimaging aspects. Int Rev Psychiatry 2007;19(4):345-57.
26. Peuskens J. The evolving definition of treatment resistance. J Clin Psychiatry 1999;60 Suppl 12:4-8. (Pubitemid 29283174)
27. Mouaffak F, Tranulis C, Gourevitch R, Poirier MF, Douki S, Olie JP, et al. Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin Neuropharmacol 2006;29(1):28-33. (Pubitemid 44378609)
28. Havaki-Kontaxaki BJ, Ferentinos PP, Kontaxakis VP, Paplos KG, Soldatos CR. Concurrent administration of clozapine and electroconvulsive therapy in clozapine-resistant schizophrenia. Clin Neuropharmacol 2006;29(1):52-6. (Pubitemid 44378611)
29. Remington G, Saha A, Chong SA, Shammi C. Augmenting strategies in clozapine-resistant schizophrenia. CNS Drugs 2005;19(10):843-72.
30. Williams L, Newton G, Roberts K, Finlayson S, Brabbins C. Clozapine-resistant schizophrenia: a positive approach. Br J Psychiatry 200;181:184-7.
31. Cervera Enguix S, Seva Fernández A. Pharmacological treatment resistant schizophrenia. Actas Esp Psiquiatr 2006;34(1):48-54.
32. Meltzer HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 1992;18(3):515-42.
33. Keefe RS, Lobel DS, Mohs RC, Silverman JM, Harvey PD, Davidson M, et al. Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms. Schizophr Res 1991;4(2):71-9.
34. Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, et al. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990;16(4):551.
35. Brenner HD, Merlo MCG. Definition of therapy resistant schizophrenia, and its assessment. Eur Psychiatr 1995;10:11-8.
36. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(2 Suppl):1-56.
37. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007;68(11 ):1751-62. (Pubitemid 350247505)
38. URL: www.ipap.org/schiz
39. European Agency for the evaluation of Medicinal Products. Committee for Proprietary Products Note for guidance on the clinical Investigatión of medicinal products in the treatment of schizophrenia. London; 1998. Report No.: paper CPMP/ EWP/559/95.
40. Elkis H. Treatment-resistant schizophrenia. Psychiatr Clin North Am 2007 Sep;30(3):511-33. (Pubitemid 47284560)
41. Pantelis C, Lambert TJ. Managing patients with " treatmentresistant" schizophrenia. Med J Aust 2003 May 5;178 Suppl:S62-S66.
42. Reis de SA Jr, Elkis H. Comments on "Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine". Rev Bras Psiquiatr 2007 Mar;29(1):90. (Pubitemid 46572475)
43. Cervera Enguix S, Seva Fernández S. Esquizofrenia resistente al tratamiento farmacologico. Act Esp Psiquiatr 2006;34(1):48-54.
44. Kraepelin, E. Psychiatry: A Textbook for Students and Physicians. 2 volumes. Edited by Jacques Quen. Translated by Helga Metoui and Sabine Ayed. Canton, Massachusetts: Science History Publications, 1990 [translation of the 1899 sixth edition].
45. McEvoy JP. Functional outcomes in schizophrenia. J Clin Psychiatry 2008;69 Suppl 3:20-4.
46. Remington G, Kapur S. Remission: what's in a name? Am J Psychiatry 2005;62(12):2393-4.
47. Bleuler M. The Schizophrenic Disorders: Long-Term Patient and Family Studies. Yale University Press, 1978, London.
48. Modestin J, Huber A, Satirli E, Malti T, Hell D. Long-term course of schizophrenic illness: Bleuler's study reconsidered. Am J Psychiatry 2003;160(12):2202-8. (Pubitemid 39619614)
49. Mason P, Harrison G, Glazebrook C, Medley I, Dalkin T, Croudace T. Characteristics of outcome in schizophrenia at 13 years. Br J Psychiatry 1995;167(5):596-603. (Pubitemid 26197768)
50. Mason P, Harrison G, Glazebrook C, Medley I, Croudace T. The course of schizophrenia over 13 years. A report from the International Study on Schizophrenia (ISoS) coordinated by the World Health Organization. Br J Psychiatry 1996;69(5):580-6.
51. Lauronen E, Koskinen J, Veijola J, Miettunen J, Jones PB, Fenton W S, e al. Recovery from schizophrenic psychoses within the Northern Finland 1966 Birth Cohort. The Journal of clinical psychiatry 2005;66 (3):375-83. (Pubitemid 40476762)
52. Wiersma D, Wanderling J, Dragomirecka E, Ganev K, Harrison G, An Der Heiden W, et al. Social disability in schizophrenia: its development and prediction over 15 years in incidence cohorts in six European centres. Psychol Med 2000;30(5):1155-67.
53. Torgalsboen AK.Rund BR. Lessons learned from three studies of recovery from schizophrenia. International Review of Psychiatry 2002;14(4):312-7. (Pubitemid 35398856)
54. Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JM, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. Clin Psychiatry 1996;57 Suppl 9:5-9. (Pubitemid 26327751)
55. Lieberman JA, Alvir JM, Koreen A, Geisler S, Chakos M, Sheitman B, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology 1996;14(3 Suppl):13S-2lS.
56. Keeney B P. Aesthetics of Change. The Guilford Press, Nueva York, 1983. Chapter 3.
57. von Foerster H. Cibernética de la Cibernética ('Cybernetics of cybernetic', 1973). Compilacion: 'Las Semillasde la Cibernética', GEDISA, Barcelona, 1 edición, 1991: capitulo 4.
58. Huxley NA, Rendall M, Sederer L Psychosocial treatments in schizophrenia: a review of the past 20 years. J Nerv Ment Dis 2000; 188(4): 187-201. (Pubitemid 30210859)
59. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia. Barcelona: Editorial Masson; 2004. Report No.: Second EdicióN.
60. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Verguowe Y, Keet IPM, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J Hummer M, Dollfus S, López-lbor JJ, Hranov LG, Gaebel W, PeuskensJ, Lindefors N, Reicher-Rossler A, Grobbee DE, for the EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-97. (Pubitemid 351418005)
61. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001;158(3):360-9. (Pubitemid 32205190)
62. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(7):1081-90. (Pubitemid 37464954)
63. Pani L, Pira L, Marchese G. Antipsychotic efficacy: relationship to optimal D2-receptor occupancy. Eur Psychiatry 2007;22(5):267-75. (Pubitemid 47096691)
64. Nnadi CU, Malhotra AK. Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics. Curr Psychiatry Rep 2007;9(4):313-8. (Pubitemid 47490003)
65. Malhotra AK, Murphy GM, Jr., Kennedy JL Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004;161(5):780-96. (Pubitemid 38625331)
66. Spina E, De Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007;100(1):4-22. (Pubitemid 46051438)
67. Chetty M, Murray M. CYP-mediated clozapine interactions: how predictable are they? Curr Drug Metab 2007;8(4):307-13. (Pubitemid 46780060)
68. Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry 1997;171:109-12. (Pubitemid 27345140)
69. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 2001 ;15(6):469-94. (Pubitemid 32601905)
70. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm 2007 Sep 15;64(18):1917-21. (Pubitemid 47462906)
71. Brady KT, Sinha R. Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress. Am J Psychiatry 2005 Aug;162(8):1483-93. (Pubitemid 41105562)
72. Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 1997;23(2):247-54. (Pubitemid 27224877)
73. Wobrock T, Soyka M. Pharmacotherapy of schizophrenia with comorbid substance use disorder-Reviewing the evidence and clinical recommendations. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(6):1375-85.
74. Brady KT, Sinha R. Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress. Am J Psychiatry 2005;162(8):1483-93. (Pubitemid 41105562)
75. Shaner A, Khalsa ME, Roberts L, Wilkins J, Anglin D, Hsieh SC. Unrecognized cocaine use among schizophrenic patients. Am J Psychiatry 1993;150(5):758-62. (Pubitemid 23137682)
76. Turner WM, Tsuang MT. Impact of substance abuse on the course and outcome of schizophrenia. Schizophr Bull 1990;16(1):87-95. (Pubitemid 20110378)
77. Batel P. Addiction and schizophrenia. Eur Psychiatry 2000 Mar;15(2):115-22. (Pubitemid 30194155)
78. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63(10):892-909. (Pubitemid 35231730)
79. Di Forti M, Morrison PD, Butt A, Murray RM. Cannabis use and psychiatric and cognitive disorders: the chicken or the egg? Curr Opin Psychiatry 2007;20(3):228-34. (Pubitemid 46588294)
80. Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM. Gene-environment interplay between cannabis and psychosis. Schizophr Bull 2008;34(6):1111-21.
81. Rathbone J, Variend H, Mehta H. Cannabis and schizophrenia. Cochrane Database Syst Rev 2008;(3):CD004837.
82. Dose M, Tempel HD. Abuse potential of anticholinergics. Pharmacopsychiatry 2000;33 Suppl 1:43-6.
83. Hughes JR, McHugh P, Holtzman S. Caffeine and schizophrenia. Psychiatr Serv 1998;49(11):1415-7. (Pubitemid 28513651)
84. Gurpegui M, Aguilar MC, Martinez-Ortega JM, Jurado D, Diaz FJ, Quintana HM, et al. Fewer but heavier caffeine consumers in schizophrenia: a case-control study. Schizophr Res 2006;86(1-3):276-83. (Pubitemid 44234043)
85. Dratcu L, Grandison A, McKay G, Bamidele A, Vasudevan V. Clozapine-resistant psychosis, smoking, and caffeine: managing the neglected effects of substances that our patients consume every day. Am J Ther 2007;14(3):314-8. (Pubitemid 46791572)
86. Potvin S, Stip E, Roy JY. Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. Int Clin Psychopharmacol 2003;18(3):121-32. (Pubitemid 36575481)
87. Goldman LS. Medical illness in patients with schizophrenia. J Clin Psychiatry 1999;60 Suppl 21:10-5. (Pubitemid 29523627)
88. Mitchell AJ, Malone D. Physical health and schizophrenia. Curr Opin Psychiatry 2006;19(4):432-7. (Pubitemid 44317873)
89. Damasio AR. Descarte's Error: Emotion, Reason and the Human Brain. A Grassel/Putman Book, New York, 1994. Chapter 6.
90. Peet M. Diet, diabetes and schizophrenia: review and hypothesis. Br J Psychiatry Suppl. 2004;47:Sl02-5.
91. Doherty WJ, Harkaway JE. Obesity and Family Systems: a Family FIRO approach to assessment and treatment planning. Journal of Marital and Family Therapy 1990;16(3):287-98.
92. Onnis L Corpo e contesto - Terapia familiare dei disturbi psicosomatici. 1985, La Nuova Italia Scientifica, Roma.
93. Cournos F, McKinnon K, Sullivan G. Schizophrenia and comorbid human immunodeficiency virus or hepatitis C virus. J Clin Psychiatry 2005;66 Suppl 6:27-33. (Pubitemid 41243259)
94. Repetto MJ, Petitto JM. Psychopharmacology in HIV-infected patients. Psychosom Med 2008;70(5):585-92.
95. Sewell DD. Schizophrenia and HIV. Schizophr Bull 1996;22(3):465-73. (Pubitemid 26295349)
96. Cloninger CR, Svrakic DM, Przybeck TR. A psychobiological model of temperament and character. Arch Gen Psychiatry 1993;50(12):975-90. (Pubitemid 23361478)
97. Cancrini L Oceano Borderline - Viajes por una patologia inexplorada. Paidos, 2007 (V edicion en italiano, 2006). Capitulo 1.
98. Polatin P. Diagnosis of schizophrenia: pseudoneurotic and other types. Int Psychiatry Clin 1964;1:735-51.
99. Ellison Z, van Os J, Murray R. Special feature: childhood personality characteristics of schizophrenia: manifestations of, or risk factors for, the disorder? J Personal Disord 1998;12(3):247-61. (Pubitemid 28463833)
100. Emsley R, Chiliza B, Schoeman R. Predictors of long-term outcome in schizophrenia. Curr Opin Psychiatry 2008;21(2):173-7. (Pubitemid 351339873)
101. Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 2007;30(3):437-52. (Pubitemid 47284561)
102. Dolder CR, Lacro JP, Leckband S, Jeste DV. Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol 2003;23(4):389-99. (Pubitemid 36951182)
103. Stone WS, Faraone SV, Seidman U, Olson EA, Tsuang MT; Consortium on the Genetics on Schizophrenia. Searching for the liabilitytoschizophrenia: conceptsand methods underlying genetic high-risk studies of adolescents. J Child Adolesc Psychopharmacol 2005;15(3):403-17. (Pubitemid 41192828)
104. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63(10):892-909. (Pubitemid 35231730)
105. Weiden PJ. Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry 2007;68Suppl 14:14-9.
106. Carpenter WT Jr, Strauss JS. The prediction of outcome in schizophrenia. IV: Eleven-year follow-up of the Washington IPSS cohort. J Nerv Ment Dis 1991;179(9):517-25.
107. Emsley R, Chiliza B, Schoeman R. Predictors of long-term outcome in schizophrenia. Curr Opin Psychiatry 2008;21(2):173-7. (Pubitemid 351339873)
108. Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia 1. Psychiatr Clin North Am 2007;30(3):437-52.
109. Dolder CR, Lacro JP, Leckband S, Jeste DV. Interventions to improve antipsychotic medication adherence: review of recent literature 5. J Clin Psychopharmacol 2003;23(4):389-99. (Pubitemid 36951182)
110. Cheung P, Schweitzer I, Crowley KC, Yastrubetskaya O.Tuckwell V. Aggressive behaviour and extrapyramidal side effects of neuroleptics in schizophrenia. Int Clin Psychopharmacol 1996;11(4):237-40. (Pubitemid 27049287)
111. Lincoln TM, Hodgins S. Is lack of insight associated with physicallyaggressivebehavioramong people with schizophrenia living in the community? J Nerv Ment Dis 2008;196(1 ):62-6.
112. Cheung P, Schweitzer I, Crowley K, Tuckwell V. Aggressive behaviour in schizophrenia: role of state versus trait factors. Psychiatry Res 1997;72(1):41-50. (Pubitemid 27428213)
113. Dolan M, Davies G. Psychopathy and institutional outcome in patients with schizophrenia in forensic settings in the UK. Schizophr Res 2006;81(2-3):277-81. (Pubitemid 43107703)
114. Abushua'leh K, Abu-Akel A. Association of psychopathic traits and symptomatology with violence in patients with schizophrenia. Psychiatry Res 2006;143(2-3):205-11. (Pubitemid 44301520)
115. Boszormenyi-Nagy I, Spark GM. Invisible Loyalties: Reciprocity in International Family Therapy. 1973, Harper and Row Pub.
116. Bowen M. The Use of Family Theory in Clinical Practice. Comprehensive Psychiatry, 7,1966:345-74. (Italian compilation: 'Dalla famiglia all'individuo. La differenziaczione del se nel sistema familiare'. Astrolabio-Ubaldini Editore, Roma, 1979).
117. Bowen M. Towards the Differentiation of Self in One's Family of Origin. Georgetown Family Symposia, vol.l, 1971-1972. (Italian compilation: 'Dalla famiglia all'individuo. La differenziaczione del se nel sistema familiare'. Astrolabio- Ubaldini Editore, Roma, 1979).
118. Alanen YO. An attempt to integrate the individual-psychological and interactional concepts of the origins of schizophrenia. Br J Psychiatry Suppl 1994 Apr;(23):56-61. (Pubitemid 24141704)
119. Cirillo S, Selvini M, Sorrentino AM. La Terapia Familiar en los Servicios Psiquiatricos. Paidos, 2004 (edicion italiana, 2002).
120. Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database Syst Rev 2010 Dec 8;(12):CD000088.
121. Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD000088. DOI: 10.1002/14651858. CD000088.pub2.
122. Selvini M. El futuro de la psicoterapia: aprender de los errores. Rev Asoc Esp Neuropsiq 2002;XXII (82):9-23.
123. Abaoub A, Vidon G. Update on "expressed emotions". Encephale 2000;26(3):81-6.
124. Kavanagh DJ. Recent developments in expressed emotion and schizophrenia. Br J Psychiatry 1992;160:601-20.
125. Siegel SJ, Irani F, Brensinger C, Kohler CG, Bilker WB, Ragland JD, et al. Prognostic Variables at Intake and Long-Term Level of Function in Schizophrenia. Am J Psychiatry 2006;163:433-41. (Pubitemid 44469385)
126. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003;28 Suppl 2:17-54. (Pubitemid 36335819)
127. Bauml J, Frobose T, Kraemer S, Rentrop M, Pitschel-Walz G. Psychoeducation: a basic psychotherapeutic intervention for patients with schizophrenia and their families. Schizophr Bull 2006;32 Suppl 1:51-59.
128. Kane JM. Treatment-resistant schizophrenic patients. J Clin Psychiatry 1996;57 Suppl 9:35-40. (Pubitemid 26327755)
129. Lieberman JA, Drake RE, Ederer LI, Belger A, Erkins D, Stroup S, et al. Science and recovery in schizophrenia. Psychiatr Serv 2008;59(5) :487-96.
130. Quintero J, Barbudo E, Molina JD, Mur C, Ceverino A, García Resa, et al. The effectiveness of the combination therapy of amisulpride and quetiapine for managing treatment-resistant schizophrenia: a naturalistic study. J. Clin Psychopharmacol 2011 Apr;31(2):240-2.